Blood
Articles in this Issue
primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma
Abstract INTRODUCTION: Patients (pts) with relapsed/refractory (R/R) follicular lymphoma FL have limited second line (2L) treatment options,...
Prothrombin complex concentrate in managing direct oral anticoagulant (DOAC)-associated bleeding and real-world use in vitamin k antagonist (VKA)-associated bleeding: The ongoing lex-210 and lex-212 studies
Abstract Background and Significance: Four-factor prothrombin complex concentrates (4F-PCCs) are approved for rapid reversal of acquired coa...
Pharmacologic overactivation of ALK activity by PTPN2/PTPN1 inhibition induces a combination of tumor-intrinsic oncogenic stress and immune responses to promote tumor eradication in ALK-positive lymphoma
Abstract Introduction Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL) is characterized by the presence of AL...
Mass spectrometry-based screening for monoclonal gammopathy in individuals undergoing physical examinations: Analyses of consecutive 15,068 cases in China
Abstract Background: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition characterized by the presence of...
Understanding chronic pain in pediatric sickle cell disease: Insights from a retrospective chart review
Abstract Background: Sickle cell disease (SCD) is an inherited hemoglobinopathy affecting over 100,000 individuals in th...
Outcomes in patients with newly diagnosed Acute Myeloid Leukemia with KMT2A rearrangement treated with cladribine, idarubicin, cytarabine (CLIA) with or without venetoclax
Abstract Background Rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML) asso...
Real-world outcomes following pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with hematologic malignancies
Abstract Background: Patients with hematologic malignancies are at significantly higher risk for severe COVID-19 due to disease-related and...
Visualizing systemic light chain amyloidosis with 18f-flutemetamol PET/CT: Correlation with biomarkers and clinical outcome
Abstract Background: Immunoglobulin light chain (AL) amyloidosis is a monoclonal plasma cell disorder characterized by t...
Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome
Abstract Background: Cutaneous T-cell lymphoma (CTCL), including Sezary syndrome (SS), is associated with high relapse rates and poor prognos...
The role of pre-existing iron deficiency anemia in hospitalizations for cardiogenic shock
Abstract Background: Iron deficiency anemia (IDA) is one of the most common hematologic disorders and has been increasingly recognized as a...
Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study
Abstract Introduction: Despite significant therapeutic advances, patients with triple-class-exposed and triple-class-refractory multiple mye...
Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib
Abstract Aims BMT CTN 1506 (“MORPHO”) was a global phase 3 study of post-hematopoietic cell transplantation (HCT) maintenance with gilteriti...
Iron deficiency anemia and health equity: Persistent gaps among reproductive-age women in the United States
Abstract Background: Iron deficiency anemia (IDA) is the most prevalent hematologic disorder among reproductive age women and a persistent p...
Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials
Abstract Introduction: Measurable residual disease (MRD) prior to consolidation therapy is a strong prognostic biomarker for relapse and lon...
Neuroinflammation detected by TSPO-PET precedes dopaminergic neuronal loss in mnt following BCMA-directed CAR-T therapy: Longitudinal multimodal neuroimaging and biomarker insights
Abstract Background: Ciltacabtagene autoleucel (cilta-cel) targets B-cell maturation antigen (BCMA) in multiple myeloma (MM). Rare, potentia...
Improvement in sickle cell disease care metrics: Regular scheduled hematology provider visits and transcranial doppler completion rate – a QI initiative at Phoenix Children's hospital
Abstract Sickle cell disease (SCD) is a multisystem hematological disorder affecting an estimated 7.74 million people world-wide and is asso...
Pre-treatment ZNF683⁺ effector CD8⁺ T cells predict response to BiTE therapy in acute lymphoblastic leukemia: Insights from single-cell and TCR sequencing
Abstract Introduction: Bispecific T cell engager (BiTE) therapy has shown meaningful activity in relapsed/refractory B-cell acute lymphoblas...
A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes
Abstract Phenotypic cell state plasticity is a key hallmark of cancer and is an intrinsic vulnerability of tumor cells. Targeting drivers of...
Impact of social determinants of health on access to molecular targeted therapy in AML and MDS: A real-world analysis
Abstract Introduction Molecularly targeted therapies (MTT) have redefined the treatment paradigm for acute myeloid leukemia (AML) and myelody...
Novel fatty acid binding protein 5 inhibitors SBFI103 and SBFI1143 impede myeloma cell fitness
Abstract Multiple myeloma (MM) involves clonal expansion of malignant plasma cells in the bone marrow. Obesity is a risk factor for developi...
Single‑cell analysis of BAX responses reveals venetoclax sensitivity and enables development of BAX‑targeting combinations in AML
Abstract Venetoclax (Ven)–based regimens have improved outcomes in acute myeloid leukemia (AML), but 20–30% of patients experience primary r...
Role efficiency in psychosocial care of sickle cell disease: A national survey of social workers
Abstract Background: Psychosocial care remains an under-recognized and inconsistently supported component of comprehensive Sickle Cell Disea...
One-year outcomes of daratumumab-based vs. non-daratumumab regimens in AL amyloidosis: A propensity-matched real-world study
Abstract Background: Daratumumab is increasingly used in the treatment of light chain (AL) amyloidosis, yet real-world comparative data on i...
Real-world characteristics of patients initiating elranatamab for relapsed/refractory multiple myeloma in the United States
Abstract Background Elranatamab is a bispecific antibody (BsAb), targeting the B-cell maturation antigen (BCMA), that was approved by the Fo...
Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study
Abstract Introduction: The CAR T cell therapy liso-cel showed promising efficacy and safety in patients with 3L+ R/R MZL in TRANSCEND FL (NC...